secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2023-12-18T23:59:59+00:00
Accession:  0001193125-23-297131
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 5.03, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viridian selects VRDN-003 as lead SC program for TED; half-life 40-50 days, pivotal mid-2024
--------------------------------------------------------------------------------

- VRDN-003 showed extended half-life of 40-50 days, 4–5× longer than VRDN-001.
- No serious adverse events; all treatment-related AEs were grade 1 (mild) and no antidrug antibodies detected.
- Modeled dosing supports once-every-8-weeks (Q8W) schedule; Q4W and Q2W also predicted to achieve robust exposure.
- VRDN-001 SC and VRDN-002 SC development deprioritized in favor of VRDN-003.
- Global pivotal trials expected to begin mid-2024 pending regulatory alignment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312523297131/0001193125-23-297131-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312523297131/d668915d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-297131

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer